/Methods For Ex Vivo Enrichment And Expansion Of Tumor Reactive T Cells And Related Compositions Thereof
Abstract
Provided herein are methods for manufacturing of tumor reactive T cells that includes ex vivo enrichment of, and expansion of, cells secreting chemokine (C—X—C motif) ligand 13 (CXCL13); cells surface positive for C—X—C chemokine receptor type 5 (CXCR5); and/or one or more of CD39, PD-1 and TIGIT. Also provided are populations of T cells produced by methods described herein and pharmaceutical compositions thereof.
Full Text
What is claimed is:
Provided herein are methods for manufacturing of tumor reactive T cells that includes ex vivo enrichment of, and expansion of, cells secreting chemokine (C—X—C motif) ligand 13 (CXCL13); cells surface positive for C—X—C chemokine receptor type 5 (CXCR5); and/or one or more of CD39, PD-1 and TIGIT. Also provided are populations of T cells produced by methods described herein and pharmaceutical compositions thereof.
Timeline
Filed
04/29/2026Published
08/20/2026Granted
Not AvailableIPC Codes(5)
A61K 40/42:Cancer antigens
A61K 40/11:T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
A61K 40/32:T-cell receptors [TCR]